Literature DB >> 11716693

Stearylated arginine-rich peptides: a new class of transfection systems.

S Futaki1, W Ohashi, T Suzuki, M Niwa, S Tanaka, K Ueda, H Harashima, Y Sugiura.   

Abstract

Membrane-permeable arginine-rich peptides, such as HIV-1 Tat-(48-60), HIV-1 Rev-(34-50), and flock house virus (FHV) coat-(35-49), have been shown to possess the ability to transfect COS-7 cells with luciferase-coding plasmid as efficiently as polyarginine (MW 5000-15 000) and polylysine (MW 9800). Not only these virus-derived cationic peptides but also oligoarginines of 4-16 residues were found to be able to transfect cells. In the case of the Tat, FHV, and octaarginine peptides, N-terminal stearylation of the peptides increases the transfection efficiency by approximately 100 times to reach the same order of magnitude as that of LipofectAMINE, one of the most efficient commercially available transfection agents. Also, a certain correlation was observed between the transfection efficiency of stearyl-(Arg)n peptides (stearyl-Rn: n = 4, 8, 12, 16) and the membrane permeability of the corresponding (Arg)n peptides (Rn).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716693     DOI: 10.1021/bc015508l

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  80 in total

1.  Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.

Authors:  Gero L Becker; Yinghui Lu; Kornelia Hardes; Boris Strehlow; Christine Levesque; Iris Lindberg; Kirsten Sandvig; Udo Bakowsky; Robert Day; Wolfgang Garten; Torsten Steinmetzer
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

Review 2.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

3.  Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons.

Authors:  Lars Tönges; Paul Lingor; Roman Egle; Gunnar P H Dietz; Alfred Fahr; Mathias Bähr
Journal:  RNA       Date:  2006-05-12       Impact factor: 4.942

4.  Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery.

Authors:  I A Khalil; K Kogure; S Futaki; S Hama; H Akita; M Ueno; H Kishida; M Kudoh; Y Mishina; K Kataoka; M Yamada; H Harashima
Journal:  Gene Ther       Date:  2007-02-01       Impact factor: 5.250

5.  Bile acid-oligopeptide conjugates interact with DNA and facilitate transfection.

Authors:  Phillip E Kish; Yasuhiro Tsume; Paul Kijek; Thomas M Lanigan; John M Hilfinger; Blake J Roessler
Journal:  Mol Pharm       Date:  2007 Jan-Feb       Impact factor: 4.939

Review 6.  Subcellular targeting strategies for drug design and delivery.

Authors:  Lawrence Rajendran; Hans-Joachim Knölker; Kai Simons
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

7.  Optimal Hydrophobicity in Ring-Opening Metathesis Polymerization-Based Protein Mimics Required for siRNA Internalization.

Authors:  Brittany M deRonde; Nicholas D Posey; Ronja Otter; Leah M Caffrey; Lisa M Minter; Gregory N Tew
Journal:  Biomacromolecules       Date:  2016-05-19       Impact factor: 6.988

8.  PKA-type I selective constrained peptide disruptors of AKAP complexes.

Authors:  Yuxiao Wang; Tienhuei G Ho; Eugen Franz; Jennifer S Hermann; F Donelson Smith; Heidi Hehnly; Jessica L Esseltine; Laura E Hanold; Mandi M Murph; Daniela Bertinetti; John D Scott; Friedrich W Herberg; Eileen J Kennedy
Journal:  ACS Chem Biol       Date:  2015-03-25       Impact factor: 5.100

9.  Enhancing the Cellular Delivery of Nanoparticles using Lipo-Oligoarginine Peptides.

Authors:  Jae Sam Lee; Ching-Hsuan Tung
Journal:  Adv Funct Mater       Date:  2012-07-27       Impact factor: 18.808

10.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.